Abstract: Techniques are provided for the prevention of reactor fouls in polymerization reactors. A technique is provided for limiting polymer particle size to prevent or limit the occurrence of reactor fouls associated with large polymer particles. A technique is also provided for measuring reactor temperature at one or more local hot spots of the reactor and for controlling the polymerization reaction based upon these temperature measurements. In particular, control of the reaction may be based on the hottest temperature, such that the hottest temperature in the reactor is maintained within the reactor fouling curve. A technique is also discussed for predicting reactor fouls by using statistical analyses, such as periodogram analysis, to identify leading indicators of impending fouls. Preventative measures may be performed upon identification of such a leading indicator. In addition, the statistical analyses may be used to identify catalysts having less propensity to foul.

Abstract: The invention relates to a method for radical polymerization of one or several ethylenically unsaturated compounds, characterized in that it consists in providing at least 80.8 percent by weight ethylenically unsaturated compounds in relation to the total weight of the ethylenically unsaturated compounds, adding at least one polymerization initiator for radical polymerization in at least two steps, wherein more polymerization initiator is added in the second step than in the first.

Abstract: Olefins are polymerised in the presence of a solid catalyst component and optionally a cocatalyst. The solid catalyst component is introduced into the polymerisation reactor by suspending the solid component into oil having a viscosity of from 20 to 1500 mPa s. Optionally, the suspension comprises a drag reduction agent dissolved in the oil. The suspension is metered into the polymerisation reactor by using a valveless piston pump.

Abstract: The present invention relates to a transition metal complex and a transition metal catalyst composition comprising the same for the preparation of an ethylene homopolymer or a copolymer of ethylene and ?-olefin. More particularly, it relates to a group IV transition metal catalyst having a cyclopentadiene derivative and at least one aryl oxide ligand in which an oxygen-containing heterocycle is fused at the ortho-position around a group IV transition metal, with no crosslinkage between the ligands, a catalyst composition comprising the transition metal catalyst and an aluminoxane cocatalyst or a boron compound cocatalyst, and a process for preparing an ethylene homopolymer or a copolymer of ethylene and ?-olefin using the same.

Abstract: A process for producing a polymer by polymerizing at least one fluorinated monomer in the presence of a radical initiator and a surfactant in a polymerization medium containing essentially only carbon dioxide. The surfactant is a functional (per)fluoropolyether having recurring units (R1) and at least one functional group containing a heteroatom other than fluorine, the recurring units containing at least one ether linkage in the main chain and at least one fluorine atom. Molded article containing the polymer obtained from the process.

Abstract: There is provided a process for the preparation of a polymerizable composition comprising a cross-linker and a polymerizable monomer of formula (I) comprising (i) contacting a compound of formula (II) with an acid such as an imobilized acid; and (ii) neutralizing product of (i) such that a crosslinker is formed.

Abstract: A novel liquid phase polymerization process for preparing a polyolefin product having preselected properties is disclosed. The process includes the steps of providing a liquid feedstock which contains an olefinic component and a catalyst composition consisting of a stable complex of BF3 and a complexing agent therefor. The feedstock may comprise any one or more of a number of olefins including branched olefins such as isobutylene, C3 to C15 linear alpha olefins and C4 to C15 reactive non-alpha olefins. The feedstock and the catalyst composition are introduced into a residual reaction mixture recirculating in a loop reactor reaction zone provided in the tube side of a shell and tube heat exchanger at a recirculation rate sufficient to cause intimate intermixing of the residual reaction mixture, the added feedstock and the added catalyst composition.

Abstract: The invention therefore relates to a process for preparation of SiOC-linked, linear (AB)d polydimethylsiloxane-polyoxyalkylene block copolymers of the general formula [(R2SiO)x(CnH2nO)y]d, in which R are monovalent C1-C18, preferably C1-C4, hydrocarbon radicals, n is a number from 2 to 4, preferably 2 or 3, x ?5, y ?10, d ?3, via reaction of aminosiloxanes having primary amino groups with polyoxyalkylenediols, which comprises concomitant use of one or more tertiary amines as catalyst.

Abstract: A cleaning blade member comprising a polyurethane formed by using a polyol consisting essentially of a polycarbonatediol, a polyisocyanate, and a crosslinking agent containing a short chain diol and a triol, the polyurethane having a tensile strength at 60° C. of 200 kg/cm2 or higher, and a tensile strength retention ?T, represented by the following equation, of 40% or more: ?T(%)=T60/T10×100 where T10 denotes a tensile strength at 10° C., and T60 denotes the tensile strength at 60° C.

Abstract: Compositions including poly(block-phophonato-esters) or poly(block-phosphonato-carbonate) and a process for making them from oligomeric phosphonates and/or polyphosphonates and polyester and/or polycarbonates are disclosed. The compositions provide tough flame retardant materials and coatings.

Abstract: A method of making polycarbonate includes the steps of forming polycarbonate by a melt transesterification method using an activated diaryl carbonate, and compounding the polycarbonate with a phosphorus-containing compound that has an abstractable proton or hydrolyzable group. The phosphorus-containing compound is compounded with the polycarbonate in an amount sufficient to result in an improvement in the color properties of the polycarbonate as compared to pellets formed from the same polycarbonate without addition of the phosphorus-containing compound.

Abstract: An aliphatic polyester copolymer comprising an aliphatic carbonate unit (a) and an aliphatic polyester unit (b), and a molded body composed of said aliphatic polyester copolymer. The aliphatic polyester copolymer is excellent in heat resistance while having adequate mechanical properties and properties in the molten state.

Abstract: Processes for preparing random polytrimethylene ether ester are provided. The processes include contacting 1,3-propanediol with a suitable polymerization catalyst, wherein the 1,3-propanediol comprises about 10 microg/g or less peroxide compounds, based on the weight of 1,3-propanediol, and about 100 microg/g or less carbonyl compounds based on the weight of the 1,3-propanediol.

Abstract: We report Michael addition products between primary amines and activated ?,?-unsaturated compounds exemplified by diethyl methylenemalonate (DEMM). In various embodiments, the reaction proceeds with high yields in the absence of strong base or Lewis acid catalyst under mild reaction conditions. Depending on the state of steric hindrance in the amine, the reaction products are a double Michael addition product or a so-called vicarious Michael addition reaction product.

Abstract: A process for preparing high-functionality highly branched polyureas which comprises reacting one or more carbonates with one or more amines having at least two primary and/or secondary amino groups, at least one amine having at least three primary and/or secondary amino groups.

Abstract: Ether nitrile co-polymers containing sulfonic acid groups, including wholly aromatic poly(aryl ether ether nitrile)s containing sulfonic acid groups (SPAEEN)s, and poly(phthalazinone ether ketone nitrile) co-polymers containing sulfonic acid groups (SPPEKN)s, intended for fuel cells applications as proton conducting membrane materials, were prepared.

Abstract: The present invention provides fragments of SNT and FGFR which can form a binding complex that is amenable to structural determinations by NMR spectroscopy. The three-dimensional structural data is also included as part of the invention. In addition, the present invention provides methodology for related structure based rational drug design using the three-dimensional data. Nucleotide and amino acid sequences of the fragments are also provided.

Abstract: A method for synthesizing a given peptide or its derivative which contains a proline residue or a proline derivative, at proximity to, or at, the C-terminal end of said peptide is provided. The method comprises a) synthesizing on a first resin a C-terminal portion of said peptide, or its derivative, comprising at least three successive amino acid residues or their derivatives, by successive coupling of selected amino acids, small peptides or their derivatives; b) cleaving the C-terminal portion from said first resin; c) reattaching said C-terminal portion to a second resin which is generally suitable for the synthesis of peptides but is unsuitable for the formation of peptides having a proline residue positioned at the C-terminal end of said peptide; and d) coupling selected amino acids, small peptides or derivatives to the C-terminal portion.

Abstract: We describe a polypeptide which binds and modulates the activity of a tumour suppressor polypeptide, for example p53; a nucleic acid molecule encoding said protein and screening methods which modulate the binding activity of said polypeptide for its target polypeptide(s).

Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.

Abstract: Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.

Abstract: The present invention provides an E-type crystal of N-demethyl-N-isopropyl-12-methoxy-11-oxo-8,9-anhydroerythromycin A-6,9-hemiacetal fumarate having strong diffraction peaks at diffraction angles (2?) of 5.6° and 10.4° as measured by powder X-ray diffractometry, which is prepared by treating a C-type crystal of the compound in a mixed solvent of ethyl acetate and water at 20° C. to 40° C., and a D-type crystal prepared via the E-type crystal. These crystals have a reduced content of residual solvent and high suitability for formulation.

Abstract: A novel strategy for monitoring the location of a transgene in a mammal is disclosed. A sodium iodide symporter is genetically fused to either the N-terminus or C-terminus of the product of a transgene through a linker peptide which bears the recognition sequence of a host cell protease. Expression of the transgene confers the activity of the sodium iodide symporter (NIS)to a host cell which expresses the transgene. Subsequent administration of labeled iodine results in transport of the labeled iodine into the cell bearing the NIS, which can then be localized and measured using standard imaging techniques. The system is particularly useful for monitoring the location of therapeutic transgenes and tissue-specific distribution of the therapeutic gene product.

Abstract: The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage.

Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.

Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PSMD10.

Abstract: Methods are provided for identifying compounds that decrease the expression or activity of an overexpressed Sprouty protein in certain cancers. Such compounds can be useful for treating cancers in which a Sprouty protein is overexpressed. Also provided are therapeutic formulations and pharmaceutical formulations for treating cancers characterized by overexpression of a Sprouty protein.

Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.

Abstract: This invention relates to galactosylceramide compounds.

Abstract: This invention relates to a process for preparing bioabsorbable oxidized cellulose comprising combining cellulose material, with nitrogen dioxide and a nonaqueous solvent chosen from the class of perfluorinated tertiary amines. This invention also relates to a method of oxidizing cellulose material comprising introducing a solvent into the vessel, circulating the solvent through the cellulose material, adding nitrogen dioxide to said vessel containing the solvent and cellulose in the required amounts, circulating the solution for 7 to 24 hours while controlling the reaction temperature, and isolating the oxidized material. Preferably, isolation of the oxidized product is followed by first washing the oxidized cellulose material with cold water, then washing the oxidized cellulose material with an aqueous alcohol solution several times, then washing the material with 100% alcohol several times, and finally drying the oxidized material.

Abstract: Disclosed is a compound of the formula wherein M is atom or group of atoms capable of bonding to central cavity of phthalocyanine molecule, wherein axial ligands optionally can be attached to M, each R? is a substituent, each n is 0, 1, 2, 3, or 4, each R? is a substituent, each m is 0, 1, 2, or 3, each R is alkylene, arylene, arylalkylene, or alkylarylene, each X is —OH, —COOH, or wherein each Y and each Z is a direct bond, oxygen, or —NR1—, wherein R1 is hydrogen, alkyl, aryl, arylalkyl, or alkylaryl, provided that Z and Y are not both direct bonds connected to a single C?O moiety at the same time, provided that when X is —COOH, R can also be a direct bond, and each Rd is alkyl, aryl, arylalkyl, or alkylaryl.

Abstract: The present invention provides processes for crystallization of macrolides, specifically pimecrolimus and tacrolimus.

Abstract: The present invention relates to unsymmetrical and symmetrical phosphorus-comprising heptazine derivatives, represented by the formula (1): in which Ra, Rb and Rc are, independently of one another, an azide group —N3 or an —N?PR1R2R3 group, with the proviso that at least one radical from Ra, Rb and Rc is an —N?PR1R2R3 group, to a process for the preparation thereof and to the use thereof.

Abstract: A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Abstract: A photosensitizer dye is provided.

Abstract: The invention relates to a novel process for preparing N-methylnaltrexone bromide, comprising at least the steps consisting in: (i) reacting N-methylnaltrexone methyl sulfate in aqueous solution with an alkaline agent chosen from the group constituted by sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, cesium carbonate, strontium carbonate and mixtures thereof, for a pH of the aqueous reaction medium of between 7 and 10, and then in (ii) reacting the product thus obtained with hydrobromic acid, which is added for a pH of the aqueous reaction medium of between 0.5 and 5, in order thus to obtain the N-methylnaltrexone bromide.

Abstract: In accordance with the present invention, compounds that can inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

Abstract: To provide a inhibitor of protein modification products formation capable of inhibiting of vitamin B6 deficiency disease as a side effect, especially a renal protective agent. There is provided a use, as an active ingredient, of any of free or salt-form compounds of either of the formulae: (I) (II) [wherein R1 is substituted or unsubstituted aromatic ring; and each of R2, R3 and R4 is a hydrogen atom or monovalent organic group, or alternatively R2 and R3 cooperate to form a condensed ring or R3 and R4 cooperate to represent a divalent organic group, provided that R3 and R4 are not simultaneously hydrogen atoms].

Abstract: Provided is a TNT replacement comprising one or more ionic liquids selected from the group of a triazolium salt, substituted triazolium salt and mixtures thereof.

Abstract: Disclosed are compositions comprising at least one [benzo[4,5]imidazo(heterocycle)] compound, said [benzo[4,5]imidazo(heterocycle)] compound selected from the group consisting of structures I and II, wherein R1 and R2 are independently selected from the group consisting of a hydrogen atom, electron withdrawing group, organic group, divalent 1,2-cycloalkylidene group, or combinations thereof; “q” is independently an integer from 1-4, L is a linking group, and “r” is independently 0 or 1; said at least one [benzo[4,5]imidazo(heterocycle)] compound being present at a concentration sufficient to cause said composition to exhibit upon exposure to an excitation radiation having a wavelength of from about 330 nanometers to about 390 nanometers, a maximum fluorescence emission wavelength of greater than or equal to about 470 nanometers; and a Stokes shift of greater than or equal to about 80 nanometers; wherein the wavelengths are measured in bisphenol A polycarbonate matrix.

Abstract: The invention provides non-steroidal ligands for the androgen receptor, methods for making non-steroidal ligands of the androgen receptor, compositions of non-steroidal ligands of the androgen receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the androgen receptor for treating or preventing diseases (e.g., prostate cancer) associated with androgen binding to the androgen receptor.

Abstract: The invention relates in a first embodiment to a method for the manufacture of esters of the formula (I), or especially of amides of the formula (II), wherein the symbols have the meanings given in the specification, as well as other intermediates and compounds useful in the synthesis of tryptamines and other substances mentioned in the title. The synthesis methods and intermediates are useful in the synthesis of pharmaceuticals.

Abstract: The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.

Abstract: A novel process of the preparation of amorphous atorvastatin calcium starting from a compound of Formula (II).

Abstract: Optically active maleimide derivatives of the formula: (where the various substituents are as defined in the description) are used as separating media for separating optical isomers and geometrical isomers such as by high performance liquid chromatography.

Abstract: A process for preparing (+)duloxetine, or an acid addition salt thereof, which process comprises resolving racemic(±)duloxetine with a chiral acid so as to obtain a salt of the chiral acid and (+)duloxetine, substantially free of (?)duloxetine; and (ii) if desired, converting the salt prepared in step (i) to the free base or another acid addition salt as appropriate. The process for preparing (+)duloxetine, or an acid addition salt thereof, can further comprise an O-alkylation intermediate process step which is carried out in the presence of a base and a phase transfer catalyst.

Abstract: This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R1a, R1b, R2b, R3a, R3b, R4, R5, R6, R7, A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.